Price cut of Faslodex

There's almost no difference in price, and 370,000won for original, and 360,000won for generic.

AstraZeneca's breast cancer treatment, Faslodex, will be a real match with Boryung's first generic Fulvet as it will be cut by 30% from the current upper limit starting next month due to a cut in drug prices following its entry into the generic.

 

This is because the price has become almost similar to Boryung Fulvet, which has the same ingredients.

 

This is a phenomenon caused by Boryung's addition to an innovative pharmaceutical company.

 

According to industries on the 25th, AstraZeneca Faslodex will be sold at 376,724 won, down 30% from the current upper limit (538,178 won per pack) from the 1st of next month.

 

Generic for Faslodex is Boryung Fulvet, which was registered on August 1st.

 

Fulvet is the only generic for Faslodex in Korea imported by Boryung from India.

 

Faslodex is a breast cancer treatment based on selective estrogen receptor decomposer (SERD) that recorded 7.5 billion won in sales based on IQVIA last year.

 

It is used for hormone receptor-positive (HR+) breast cancer, which accounts for 80% of breast cancer, but it has not been long since it was approved in Korea in 2007, and started selling it in earnest after receiving a salary in 2019.

 

In the meantime, it is analyzed that product competitiveness has also decreased with the emergence of new breast cancer drugs.

 

The industry believes that there is a high possibility of growth in the future because oral CDK4/6 inhibitors such as Pfizer Ibrance and secondary treatment combined therapy are also receiving benefits.

 

This is why Boryung introduced the first generic in India.

 

Boryung also received additional benefits when it registered Fulvet's benefit in August.

 

It was listed at 68% of the original upper limit.

 

Given that general generics are set at 53.55%, the Fulvet price can be seen as high.

 

It can be seen that the gap between the two products has almost disappeared as the original was cut to 70%.

 

The original Faslodex is 376,724 won and the first generic Fulvet is 365,961 won, which are only about 10,000 won apart.

 

Usually, there is a difference in drug prices because the original is set at 70% of the existing upper limit and the generic is set at 53.55%, but in the case of Fulvet, there is virtually no difference in drug prices from the first year.

 

The two products will be the same at 288,194 won from August next year.

 

Boryung is a leading anti-cancer drug manufacturer among domestic pharmaceutical companies, so it is predicted that it can sufficiently threaten the original with its sales power.

 

In the future, competition between AstraZeneca and Boryung, Korea, is drawing attention.